Summit Therapeutics tumbles 13% after FDA rejects lung cancer drug application
Summit Therapeutics (SMMT) shares dropped 13% after the FDA rejected its lung cancer drug application, citing insufficient overall survival benefit. The HARMONi trial showed improved progression-free survival but missed the statistical significance threshold for overall survival. Jefferies noted the decision was anticipated and maintained focus on the upcoming HARMONi-3 trial results.
How this was made

The 30-second read
Why it matters
The denial eliminates a near‑term revenue opportunity and underscores the importance of overall survival data. The stock's 13% drop reflects immediate market reaction.
Market read
Regulatory outcome directly affects Summit's valuation and may influence sentiment toward similar biotech firms awaiting FDA decisions.
What to watch
Analyst Jefferies still sees value in the first‑line pipeline; the rejection may be priced in already for the second‑line asset.
Background
Summit Therapeutics (NASDAQ:SMMT) is a clinical‑stage biotech focused on lung cancer therapies. The FDA rejection pertains to its ivonescimab plus chemotherapy regimen for EGFR‑mutated NSCLC.
Ticker impact
FDA issued a complete response letter rejecting Summit Therapeutics' lung cancer drug application, causing the stock to tumble 13%.
downward pressure as investors reassess valuation without the anticipated approval.
Regulatory denial removes a major catalyst; the stock already fell 13% on the news and no alternative near‑term catalyst is evident.
Market effects
Biotech sector may see broader risk‑off pressure on other companies awaiting FDA approvals.
U.S. biotech indices could dip modestly as investors react to the regulatory setback.
Limited to markets with exposure to U.S. biotech stocks; no major macro impact.
Counterpoint
If the company can pivot to its first‑line trial data later in 2026, the stock may recover on new positive data.
Key entities
- companySummit Therapeutics
Biotech developer of lung cancer therapies.
- regulatorFDA
U.S. Food and Drug Administration, issuer of the rejection letter.




